-
EP2624858
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP2624858
| EP2624858 - USE OF A PHOSPHOPEPTIDE ABLE TO BLOCK HER3/P85 INTERACTION FOR THE TREATMENT OF HER2 HYPER-EXPRESSING TUMOURS [Right-click to bookmark this link] | Status | The application is deemed to be withdrawn Status updated on 21.08.2015 Database last updated on 06.07.2024 | Most recent event Tooltip | 21.08.2015 | Application deemed to be withdrawn | published on 23.09.2015 [2015/39] | Applicant(s) | For all designated states Istituti Fisioterapici Ospitalieri (IFO) Via Elio Chianesi 53 00144 Roma / IT | [N/P] |
| Former [2013/33] | For all designated states Istituti Fisioterapici Ospitalieri (IFO) Via Elio Chianesi 53 00128 Roma / IT | Inventor(s) | 01 /
FALCIONI, Rita Via Diego Fabbri I-00137 Roma / IT | 02 /
FOLGIERO, Valentina Via Sant'Erasmo 14 I-00184 Roma / IT | 03 /
DI CARLO, Selene Eleonora Via Cefalù 28 I-00040 Torvaianica (RM) / IT | 04 /
BON, Giulia Via Claudio Asello 49 I-00178 Roma / IT | [2013/33] | Representative(s) | Gitto, Serena, et al Barzanò & Zanardo Roma S.p.A. Via Piemonte, 26 00187 Roma / IT | [N/P] |
| Former [2013/33] | Gitto, Serena, et al Barzanò & Zanardo Roma S.p.A. Via Piemonte, 26 00187 Roma / IT | Application number, filing date | 11782682.6 | 29.09.2011 | WO2011IT00336 | Priority number, date | IT2010RM00517 | 04.10.2010 Original published format: IT RM20100517 | [2013/33] | Filing language | IT | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2012046260 | Date: | 12.04.2012 | Language: | EN | [2012/15] | Type: | A1 Application with search report | No.: | EP2624858 | Date: | 14.08.2013 | Language: | EN | The application published by WIPO in one of the EPO official languages on 12.04.2012 takes the place of the publication of the European patent application. | [2013/33] | Search report(s) | International search report - published on: | EP | 12.04.2012 | Classification | IPC: | A61K38/18, A61P35/00, A61K31/138, A61K31/337, A61K31/555, A61K31/675, A61K31/704, A61K39/395 | [2013/33] | CPC: |
A61K31/138 (EP,US);
A61K38/10 (EP,US);
A61K31/337 (EP,US);
A61K31/555 (EP,US);
A61K31/675 (EP,US);
A61K31/704 (EP,US);
A61K38/1808 (EP,US);
A61K39/39558 (EP,US);
A61K45/06 (US);
| C-Set: |
A61K31/138, A61K2300/00 (US,EP);
A61K31/337, A61K2300/00 (US,EP);
A61K31/555, A61K2300/00 (US,EP);
A61K31/675, A61K2300/00 (US,EP);
A61K31/704, A61K2300/00 (EP,US);
A61K38/1808, A61K2300/00 (EP,US); | Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2013/33] | Title | German: | VERWENDUNG EINES DIE HER3/P85-INTERAKTION BLOCKIERENDEN PHOSPHOPEPTIDS ZUR BEHANDLUNG VON HER2-ÜBEREXPRIMIERENDEN TUMOREN | [2013/33] | English: | USE OF A PHOSPHOPEPTIDE ABLE TO BLOCK HER3/P85 INTERACTION FOR THE TREATMENT OF HER2 HYPER-EXPRESSING TUMOURS | [2013/33] | French: | UTILISATION D'UN POLYPEPTIDE CAPABLE DE BLOQUER L'INTERACTION HER3/P85 DANS LE TRAITEMENT DE TUMEURS HYPER-EXPRIMANT HER2 | [2013/33] | Entry into regional phase | 20.03.2013 | National basic fee paid | 20.03.2013 | Designation fee(s) paid | 20.03.2013 | Examination fee paid | Examination procedure | 20.03.2013 | Examination requested [2013/33] | 05.11.2013 | Amendment by applicant (claims and/or description) | 01.04.2015 | Application deemed to be withdrawn, date of legal effect [2015/39] | 20.05.2015 | Despatch of communication that the application is deemed to be withdrawn, reason: renewal fee not paid in time [2015/39] | Fees paid | Renewal fee | 19.09.2013 | Renewal fee patent year 03 | Penalty fee | Additional fee for renewal fee | 30.09.2014 | 04 M06 Not yet paid |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Cited in | International search | [A]WO03080835 (ZENSUN SHANGHAI SCI TECH LTD [CN], et al) [A] 1-14 * claims 4,11; sequence 1 *; | [A]US7705130 (ROTHE MIKE [DE], et al) [A] 1-14 * examples 19,20,22-25,27 *; | [AP]WO2011022727 (MERRIMACK PHARMACEUTICALS INC [US], et al) [AP] 1-14 * the whole document * * example 18 *; | [AD] - SUENAGA ATSUSHI ET AL, "Novel mechanism of interaction of p85 subunit of phosphatidylinositol 3-kinase and ErbB3 receptor-derived phosphotyrosyl peptides.", THE JOURNAL OF BIOLOGICAL CHEMISTRY 14 JAN 2005 LNKD- PUBMED:15520002, (20050114), vol. 280, no. 2, ISSN 0021-9258, pages 1321 - 1326, XP002648031 [AD] 1-14 * the whole document * DOI: http://dx.doi.org/10.1074/JBC.M410436200 | [AD] - HELLYER ET AL, "ErbB3 (HER3) interaction with the p85 regulatory subunit of phosphoinositide 3-kinase.", BIOCHEMICAL JOURNAL, (19980801), vol. 333, no. 3, ISSN 0264-6021, pages 757 - 63, XP055002118 [AD] 1-14 * the whole document * DOI: http://dx.doi.org/10.1042/bj3330757 | by applicant | - KLAPPER LN; KIRSCHBAUM MH; SELA M; YARDEN Y, "Biochemical and clinical implications of the ErbB/ HER signaling network of growth factor receptors", ADVANCES IN CANCER RES., (2000), vol. 77, pages 25 - 79, XP009122902 | - HYNES NE; LANE HA, "ERBB receptors and cancer: the complexity of target inhibitor", NAT REV CANCER, (2005), vol. 5, pages 341 - 54 | - YARDEN Y., "Biology of HER2 and its importance in breast cancer", ONCOLOGY, (2001), vol. 61, doi:doi:10.1159/000055396, pages 1 - 13, XP009041443 DOI: http://dx.doi.org/10.1159/000055396 | - COOKE T; REEVES J; LANIGAN A; STRANTON P., "HER2 as prognostic and predective marker for breast cancer", ANN. ONCOL., (2001), vol. 12, pages S23 - S28 | - SLAMON DJ; LEYLAND-JONES B; SHAK S ET AL., "Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2", N ENGL J MED, (2001), vol. 344, doi:doi:10.1056/NEJM200103153441101, pages 783 - 92, XP008019806 DOI: http://dx.doi.org/10.1056/NEJM200103153441101 | - FRESNO VARA JA; CASADO E; DE CASTRO J; CEJAS P; BELDA-INIESTA C; GONZALES-BARON M., "P13K/Akt signaling pathway and cancer", CANCER TREAT. REVIEWS, (2004), vol. 30, pages 193 - 204 | - "Akt kinases in breast cancer and the results of adjuvant therapy", BREAST CANCER RES., (2003), vol. 5, pages R37 - R44 | - BERNS K; HORLINGS HM; HENNESSY BT ET AL., "A functional genetic approach identifies the P13K pathway as a major determinant of trastuzumab resistance in breast cancer", CANCER CELL, (2007), vol. 12, pages 395 - 402 | - WALLASCH C; WEISS FU; NIEDERFELL G ET AL., "Heregulin-dependent regulation of HER2/neu oncogene by heterodimerization with HER3", EMBO J., (1995), vol. 14, pages 4267 - 75, XP002034011 | - HOLBRO T; BEERLI RR; MAURER F ET AL., "The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor proliferation", PROC NATL ACAD SCI USA, (2003), vol. 108, doi:doi:10.1073/pnas.1537685100, pages 8933 - 8, XP002684949 DOI: http://dx.doi.org/10.1073/pnas.1537685100 | - LEARY JM; SHAPIRO GI., "Development of phosphoinositide-3 kinase pathway inhibitors for advanced cancer", CURR. ONCOL. REP., (2010), vol. 12, pages 87 - 94 | - FOLGIERO V; AVETRANI P; BON G ET AL., "Induction of ErbB-3 expression by alpha6beta4 integrin contributes to tamoxifen resistance in ERbetal- negative breast cancinomas", PLOS ONE, (2008), vol. 13, page E1592 | - HELLYER NJ; CHENG K; KOLAND JG, ERBB3 (HER3) INTERACTION WITH P85 REGULATORY SUBUNIT | - SUENAGA A; TAKADA N; HATAKEYAMA M ET AL., "Novel mechanism of interaction of p85 subunit of phosphatidylinositol 3-kinase and ErbB3 receptor-derived phosphotyrosyl peptides", J. BIOL. CHEM., (2005), vol. 280, doi:doi:10.1074/JBC.M410436200, pages 1321 - 6, XP002648031 DOI: http://dx.doi.org/10.1074/JBC.M410436200 | - FOLGIERO V; BACHELDER R; BON G ET AL., "The alpha6beta4 integrin can regulate ErbB-3 expression: implications for alpha6beta4 signaling and function", CANCER RES., (2007), vol. 67, pages 1645 - 52 | - SIGNORE A; MATHER SJ; PIAGGIO G ET AL., "Molecular imaging of inflammation/infection: nuclear medicine and optical imaging agents and methods", CHEM REV., (20100512), vol. 110, no. 5, pages 3112 - 45 | - VIROS A.; FRIDLYAND J.; BAUER J. ET AL., "Improving Melanoma classification by integrating genetic and morphologic features", PLOS MEDICINE, (2008), vol. 5, page E120 | - BON G; FOLGIERO V; BOSSI G ET AL., "Loss of beta4 integrin subunit reduces the tumorigenicity of MCF7 mammay cells and causes apoptosis upon hormone deprivation", CLIN. CANCER RES., (2006), vol. 12, pages 3280 - 7 |